Trastuzumab Emtansine
Hormone Receptor Negative Tumor
QuantumLeap Healthcare Collaborativeantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
71 Active assets in the Hormone Receptor Negative Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivoceranib Fudan University | Phase 2 | CCC |
tqb2868 Fudan University | Phase 2 | CCC |
Rilvegostomig QuantumLeap Healthcare Collaborative | Phase 2 | CCC |
Sarilumab QuantumLeap Healthcare Collaborative | Phase 2 | CCC |
Irinotecan QuantumLeap Healthcare Collaborative | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
Trastuzumab Emtansine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →